Feigelson Heather Spencer, Goddard Katrina A B, Hollombe Celine, Tingle Sharna R, Gillanders Elizabeth M, Mechanic Leah E, Nelson Stefanie A
Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA, Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA and Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA and.
Carcinogenesis. 2014 Oct;35(10):2157-63. doi: 10.1093/carcin/bgu165. Epub 2014 Aug 12.
Cancer is characterized by a diversity of genetic and epigenetic alterations occurring in both the germline and somatic (tumor) genomes. Hundreds of germline variants associated with cancer risk have been identified, and large amounts of data identifying mutations in the tumor genome that participate in tumorigenesis have been generated. Increasingly, these two genomes are being explored jointly to better understand how cancer risk alleles contribute to carcinogenesis and whether they influence development of specific tumor types or mutation profiles. To understand how data from germline risk studies and tumor genome profiling is being integrated, we reviewed 160 articles describing research that incorporated data from both genomes, published between January 2009 and December 2012, and summarized the current state of the field. We identified three principle types of research questions being addressed using these data: (i) use of tumor data to determine the putative function of germline risk variants; (ii) identification and analysis of relationships between host genetic background and particular tumor mutations or types; and (iii) use of tumor molecular profiling data to reduce genetic heterogeneity or refine phenotypes for germline association studies. We also found descriptive studies that compared germline and tumor genomic variation in a gene or gene family, and papers describing research methods, data sources, or analytical tools. We identified a large set of tools and data resources that can be used to analyze and integrate data from both genomes. Finally, we discuss opportunities and challenges for cancer research that integrates germline and tumor genomics data.
癌症的特征是种系基因组和体细胞(肿瘤)基因组中发生的多种基因和表观遗传改变。已经鉴定出数百种与癌症风险相关的种系变异,并且已经生成了大量识别参与肿瘤发生的肿瘤基因组中突变的数据。越来越多地,人们开始联合探索这两个基因组,以更好地了解癌症风险等位基因如何促进致癌作用,以及它们是否影响特定肿瘤类型的发展或突变谱。为了了解种系风险研究数据和肿瘤基因组分析数据是如何整合的,我们回顾了2009年1月至2012年12月期间发表的160篇描述整合了这两个基因组数据的研究文章,并总结了该领域的现状。我们确定了使用这些数据解决的三种主要研究问题类型:(i)利用肿瘤数据确定种系风险变异的推定功能;(ii)识别和分析宿主遗传背景与特定肿瘤突变或类型之间的关系;(iii)利用肿瘤分子分析数据减少遗传异质性或完善种系关联研究的表型。我们还发现了比较基因或基因家族中种系和肿瘤基因组变异的描述性研究,以及描述研究方法、数据来源或分析工具的论文。我们确定了大量可用于分析和整合来自两个基因组数据的工具和数据资源。最后,我们讨论了整合种系和肿瘤基因组学数据的癌症研究的机遇和挑战。